🔓 Unlock the full profile of Chaitanya Devendra (Axxelent Pharma Science Pvt Ltd), including verified contact details, financial insights, and professional associations.

See Chaitanya Devendra Full Profile

Below are the ✅ Verified Contact Details to help you connect directly:

Email: cha*****@axx******.com

Mobile: 77729*****

Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)

Key Insights You Should Know About This Individual

  • Chaitanya Devendra co-founded Axxelent Pharma Science Pvt Ltd in April 2022, taking on the role of Chief Business Officer, demonstrating leadership and entrepreneurial spirit in the pharmaceutical sector.
  • In addition to Axxelent, Chaitanya founded Avanthiya Pharma in September 2021, an initiative aimed at expanding capabilities and offerings in the pharmaceutical industry.
  • Previously held the position of Head - Global Sales & Marketing for Ibuprofen & Derivatives at Solara Active Pharma Sciences from November 2015 until September 2021, where responsibilities included strategizing global sales efforts and expanding market outreach.
  • Served as Associate Vice President at Solara Active Pharma Sciences from August 2019 to August 2021, indicating a progressive leadership role focused on enhancing business operations and market performance.
  • Worked in Business Development at Shasun from June 2009 to September 2021, contributing to strategic partnerships and driving business growth in competitive environments.
  • Axxelent Pharma Science Pvt Ltd aims to innovate within the pharmaceutical landscape, with Chaitanya orchestrating key business strategies and operational frameworks.
  • Achievements in previous roles at Solara include successfully launching and marketing products globally while managing extensive sales teams, set against the backdrop of industry challenges such as market saturation and regulatory compliance.
  • Chaitanya has consistently focused on creating sustainable growth opportunities and fostering collaborations that enhance product distribution and research initiatives.